Search results for "Myers Squibb"
Dasatinib CA180003 BMS-354825 Clinical Study Report Name of Sponsor/Company: Bristol-Myers Squibb Individual Study Table Referring to the Dossier
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Unresectable or Metastatic Melanoma • OPDIVO® (nivolumab) as a single agent is indicated for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma [see Clinical Studies (14.1)].
2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Refractory Testicular Tumors ETOPOPHOS is indicated, in combination with other chemotherapeutic drugs, for treatment of
Page 3 of 4 Bristol-Myers Squibb Patient Assistance Foundation (BMSPAF) Patient Agreement and Consent I promise that: • All of the information I provided in my application, and other documents or information that I
center for drug evaluation and research . application number: 125554orig1s000 . summary review
Plastibase Bristol-Myers Squibb Company 000000000921 Page 2 of 2 End of Safety Data Sheet 3. HAZARDS IDENTIFICATION Environmental Effects Experimental data indicate low potential for acute harm to aquatic organisms. 4. FIRST AID MEASURES Eye contact Rinse immediately with plenty of water for at least 15 minutes.
11 I T AY ’ S D ION Our Approach The approach that we will discuss today is very similar to that used by Bristol-Myers Squibb. In fact, almost every large pharmaceutical company uses the
Paclitaxel is a natural product with antitumor activity. TAXOL (paclitaxel) is obtained via a semi-synthetic process from . Taxus baccata. The chemical name for paclitaxel is
Related search results
SYNOPSIS, Myers Squibb, Nivolumab, ETOPOPHOS, Bristol-Myers Squibb Patient Assistance, Bristol-Myers Squibb Patient Assistance Foundation, 125554orig1s000, Food and Drug Administration, Material Safety Data Sheet, Valuation Analysis in Pharmaceutical Licensing, Paclitaxel